There are 2949 resources available
1587MO - How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature
Presenter: Karla Hernandez Villafuerte
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1588MO_PR - A comparative study on costs of cancer and access to medicines in Europe
Presenter: Nils Wilking
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1589MO - Opposition to a patent covering tisagenlecleucel: Using intellectual property (IP) legislation to defend sustainable access to cancer therapies
Presenter: Juliana Veras
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1590MO - Income loss after a cancer diagnosis from the patient perspective: An analysis based upon the German Socio-Economic Panel (SOEP) survey
Presenter: Diego Hernandez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
LBA26 - Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
Presenter: Ramaprasad Srinivasan
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
703MO - An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution
Presenter: Yue Zhao
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA27 - Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
Presenter: Begona Perez Valderrama
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
704MO - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
Presenter: Petros Grivas
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
705MO - Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
Presenter: Pavlos Msaouel
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA20 - Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Presenter: Robert Jones
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast